Quick Answer
Harmony Biosciences Holdings, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $868.45 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +21.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 14,386.3%.
- Historical annual values: Fiscal year 2025: $868.45 million | Fiscal year 2024: $714.73 million | Fiscal year 2023: $582.02 million | Fiscal year 2022: $437.86 million | Fiscal year 2021: $305.44 million | Fiscal year 2020: $159.74 million | Fiscal year 2019: $6.00 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: